Save your place

Sign in to WhoBought

Please try again later.

CytomX Therapeutics, Inc. (CTMX) institutional ownership

Latest close $3.10 Jul 31, 2026
Market cap$552M 52-week range SectorHealthcare
Funds holding · Q1 2026
177
reported CTMX position changes
Top owners · Q2 2026
No disclosed owners are available.
Institutional activity · Q1 2026
Activity unavailable N/A
130 buyers · 47 sellers

CytomX Therapeutics, Inc. (CTMX) price and institutional activity

Dates

Q1 2026

$0 bought by 130 investors
Bank of America CorpFMR LLC +128 more
$0 sold by 47 investors
Commodore Capital LPVenrock Adviser, LLC +45 more
Bought Sold Totals per quarter; hover a bar for the names.

CytomX Therapeutics, Inc. (CTMX) institutional activity · 47

Investor Type Est. change Change Δ Own Date
Commodore Capital LP · Exited
Change −7.7M Δ Own −100.0% Date Q1 2026
Commodore Capital LP Exited· Q1 2026 −7.7M −100.0% Q1 2026
Venrock Adviser, LLC · Reduced
Change −5.6M Date Q1 2026
Venrock Adviser, LLC Reduced· Q1 2026 −5.6M Q1 2026
Financial Engines Advisors L.L.C. · Exited
Change −3.8M Δ Own −100.0% Date Q1 2026
Financial Engines Advisors L.L.C. Exited· Q1 2026 −3.8M −100.0% Q1 2026
Orbimed Advisors LLC · Exited
Change −3.5M Δ Own −100.0% Date Q1 2026
Orbimed Advisors LLC Exited· Q1 2026 −3.5M −100.0% Q1 2026
Ikarian Capital, LLC · Exited
Change −3.2M Δ Own −100.0% Date Q1 2026
Ikarian Capital, LLC Exited· Q1 2026 −3.2M −100.0% Q1 2026
Balyasny Asset Management L.P. · Reduced
Change −3.1M Date Q1 2026
Balyasny Asset Management L.P. Reduced· Q1 2026 −3.1M Q1 2026
Vivo Capital, LLC · Exited
Change −2.9M Δ Own −100.0% Date Q1 2026
Vivo Capital, LLC Exited· Q1 2026 −2.9M −100.0% Q1 2026
Stempoint Capital LP · Exited
Change −1.0M Δ Own −100.0% Date Q1 2026
Stempoint Capital LP Exited· Q1 2026 −1.0M −100.0% Q1 2026
Goldman Sachs Group Inc · Reduced
Change −1.0M Date Q1 2026
Goldman Sachs Group Inc Reduced· Q1 2026 −1.0M Q1 2026
Boothbay Fund Management, LLC · Reduced
Change −880K Date Q1 2026
Boothbay Fund Management, LLC Reduced· Q1 2026 −880K Q1 2026
Acadian Asset Management LLC · Reduced
Change −792K Date Q1 2026
Acadian Asset Management LLC Reduced· Q1 2026 −792K Q1 2026
Adar1 Capital Management, LLC · Reduced
Change −773K Date Q1 2026
Adar1 Capital Management, LLC Reduced· Q1 2026 −773K Q1 2026
Silverarc Capital Management, LLC · Exited
Change −386K Δ Own −100.0% Date Q1 2026
Silverarc Capital Management, LLC Exited· Q1 2026 −386K −100.0% Q1 2026
Woodline Partners LP · Reduced
Change −336K Date Q1 2026
Woodline Partners LP Reduced· Q1 2026 −336K Q1 2026
Two Sigma Advisers, LP · Exited
Change −336K Δ Own −100.0% Date Q1 2026
Two Sigma Advisers, LP Exited· Q1 2026 −336K −100.0% Q1 2026
Data through Q1 2026 · filed Jun 4, 2026
15 of 47

Famous investor activity in CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. (CTMX) insider trading

Company insiders, action and economics first; trade and filed dates last.
Dates
Insider Title Type Price Qty Value Owned ΔOwn Trade date Filed date
Fuchs Charles S. · Director Grant (A) 118K
Owned 118K Trade date Jul 24, 2026 Filed date Jul 30, 2026
Fuchs Charles S. Director Grant (A) 118K 118K Jul 24, 2026 Jul 30, 2026
Su Zhen · Director Grant (A) 59K
Owned 59K Trade date Jun 17, 2026 Filed date Jun 22, 2026
Su Zhen Director Grant (A) 59K 59K Jun 17, 2026 Jun 22, 2026
Young Matthew P. · Director Grant (A) 59K
Owned 59K Trade date Jun 17, 2026 Filed date Jun 22, 2026
Young Matthew P. Director Grant (A) 59K 59K Jun 17, 2026 Jun 22, 2026
Mohindru Mani · Director Grant (A) 59K
Owned 59K Trade date Jun 17, 2026 Filed date Jun 22, 2026
Mohindru Mani Director Grant (A) 59K 59K Jun 17, 2026 Jun 22, 2026
Meyers James R. · Director Grant (A) 59K
Owned 59K Trade date Jun 17, 2026 Filed date Jun 22, 2026
Meyers James R. Director Grant (A) 59K 59K Jun 17, 2026 Jun 22, 2026
Gilbert Halley E. · Director Grant (A) 59K
Owned 59K Trade date Jun 17, 2026 Filed date Jun 22, 2026
Gilbert Halley E. Director Grant (A) 59K 59K Jun 17, 2026 Jun 22, 2026
Ashworth Alan · Director Grant (A) 59K
Owned 59K Trade date Jun 17, 2026 Filed date Jun 22, 2026
Ashworth Alan Director Grant (A) 59K 59K Jun 17, 2026 Jun 22, 2026
Jones Elaine V · Director Grant (A) 59K
Owned 59K Trade date Jun 17, 2026 Filed date Jun 22, 2026
Jones Elaine V Director Grant (A) 59K 59K Jun 17, 2026 Jun 22, 2026
Ogden Christopher · CFO Sell −$5K
Price $3.05 Qty −2K Owned 295K Trade date Jun 15, 2026 Filed date Jun 17, 2026
Ogden Christopher CFO Sell $3.05 −2K −$5K 295K Jun 15, 2026 Jun 17, 2026
Chu Yu-Waye · Officer Sell −$137K
Price $6.42 Qty −21K Owned 189K Trade date Mar 17, 2026 Filed date Mar 19, 2026
Chu Yu-Waye Officer Sell $6.42 −21K −$137K 189K Mar 17, 2026 Mar 19, 2026
McCarthy Sean A. · Director, Officer Sell −$764K
Price $6.42 Qty −119K Owned 1.1M Trade date Mar 17, 2026 Filed date Mar 19, 2026
McCarthy Sean A. Director, Officer Sell $6.42 −119K −$764K 1.1M Mar 17, 2026 Mar 19, 2026
Belvin Marcia · Officer Sell −$202K
Price $6.42 Qty −31K Owned 301K Trade date Mar 17, 2026 Filed date Mar 19, 2026
Belvin Marcia Officer Sell $6.42 −31K −$202K 301K Mar 17, 2026 Mar 19, 2026
Ogden Christopher · Officer Sell −$124K
Price $6.42 Qty −19K Owned 297K Trade date Mar 17, 2026 Filed date Mar 19, 2026
Ogden Christopher Officer Sell $6.42 −19K −$124K 297K Mar 17, 2026 Mar 19, 2026
Lester Rachael · Officer 3 operations 120K
Owned 50K Trade date Feb 2, 2026 Filed date Feb 4, 2026
Lester Rachael Officer 3 operations 120K 50K Feb 2, 2026 Feb 4, 2026
Chu Yu-Waye · Officer 2 operations 375K
Owned 300K Trade date Feb 2, 2026 Filed date Feb 4, 2026
Chu Yu-Waye Officer 2 operations 375K 300K Feb 2, 2026 Feb 4, 2026
15 of 24
15 of 24 Sign in to continue to older insider transactions.

CytomX Therapeutics, Inc. (CTMX) activist and large shareholders

Dates
Owner/Filer identity Shares reported % of shares outstanding Filing date
Tang Capital Partners LP 6.5M
% of shares outstanding 9.8% Filing date Feb 14, 2024
Tang Capital Partners LP 6.5M 9.8% Feb 14, 2024
Blackrock, Inc. 16.6M
% of shares outstanding 7.6% Filing date Jul 27, 2026
Blackrock, Inc. 16.6M 7.6% Jul 27, 2026
Tang Capital Management LLC 11.1M
% of shares outstanding 7.0% Filing date Aug 14, 2025
Tang Capital Management LLC 11.1M 7.0% Aug 14, 2025
Kynam Capital Management, LP 0
% of shares outstanding 6.9% Filing date May 15, 2026
Kynam Capital Management, LP 0 6.9% May 15, 2026
Janus Henderson Group PLC 4.8M
% of shares outstanding 6.2% Filing date Nov 14, 2024
Janus Henderson Group PLC 4.8M 6.2% Nov 14, 2024
Vanguard Group Inc 9.4M
% of shares outstanding 6.0% Filing date Jul 29, 2025
Vanguard Group Inc 9.4M 6.0% Jul 29, 2025
FMR LLC 9.2M
% of shares outstanding 5.9% Filing date Aug 6, 2025
FMR LLC 9.2M 5.9% Aug 6, 2025
Longitude Capital Partners V, LLC 12.5M
% of shares outstanding 5.7% Filing date May 15, 2026
Longitude Capital Partners V, LLC 12.5M 5.7% May 15, 2026
8 of 16

CytomX Therapeutics, Inc. (CTMX) ownership FAQ

Who owns CTMX?

177 reporting institutions disclosed CTMX position changes in the Q1 2026 snapshot.

How is institutional activity calculated?

For each manager, WhoBought compares accepted consecutive 13F share counts. Share change is current shares minus prior shares. Estimated dollar change is that signed share change multiplied by the split-adjusted quarter-mean close. The activity table on this page uses Q1 2026.

What are activist and large shareholder filings?

An investor crossing 5% of a share class generally files Schedule 13D for activist intent or Schedule 13G for a passive position. The technical form names appear here rather than in the activity rows.

Where does this data come from?

Ownership and institutional activity come from SEC Form 13F filings. Insider activity comes from SEC Form 4, and large-shareholder activity from SEC Schedules 13D and 13G. FMP supplies price data only. Company logos use the local verified Parqet cache with one shared fallback.

Why are ownership reports delayed?

Form 13F is a quarterly disclosure and is normally filed after the quarter ends. Every ownership and activity value therefore names its represented period; it is not presented as a live position.

How are missing table values shown?

A muted dash marks a missing table value. It means the filing omitted the value, comparable data is unavailable, or no prior position exists for comparison.